Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

EMA Emera Inc.

交易中 09-17 12:55:36 EDT

49.48

+0.59

+1.21%

最高49.53	最低49.08	成交量5.11万
今开49.10	昨收48.89	日振幅0.92%
总市值151.30亿	流通市值151.30亿	总股本3.06亿
成交额251.75万	换手率0.02%	流通股本3.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"EMA","market":"US","secType":"STK","nameCN":"Emera Inc.","latestPrice":49.48,"timestamp":1789664127671,"preClose":48.89,"halted":0,"volume":51055,"delay":0,"changeRate":0.012067907547555662,"floatShares":305783111,"shares":305783111,"eps":2.229761,"marketStatus":"交易中","change":0.59,"latestTime":"09-17 12:55:36 EDT","open":49.1,"high":49.53,"low":49.08,"amount":2517474.211465,"amplitude":0.009204,"askPrice":49.49,"askSize":21,"bidPrice":49.48,"bidSize":500,"shortable":3,"etf":0,"ttmEps":2.229761,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"NYSE","adjPreClose":48.89,"dividendRate":0.042618,"postHourTrading":{"tag":"盘后","latestPrice":48.89,"preClose":48.89,"latestTime":"19:30 EDT","volume":27131,"amount":1328005.013608,"timestamp":1789601405082,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.35496,"impliedVol":0.3708,"impliedVolPercentile":0.9363},"requestUrl":"/m/hq/s/EMA","defaultTab":"news","newsList":[{"id":"2662639772","title":"伯维（ABBV）向EMA递交Skyrizi克罗恩病治疗上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2662639772","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662639772?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:56","pubTimestamp":1787821007,"startTime":"0","endTime":"0","summary":"Skyrizi此前已经在银屑病、银屑病关节炎等多个自身免疫疾病领域拿到欧洲地区的获批资质，如若本次克罗恩病适应症顺利获批，将进一步拓宽该产品在欧洲炎症性肠病赛道的市场空间。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305377","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RXL","SG9999001440.SGD","FHLC","LU0661504455.SGD","IYH","LU2133065610.SGD","SG9999011175.SGD","LU1585245621.USD","LU1267930573.SGD","BK4533","LU0114720955.EUR","LU0289739699.SGD","LU2237443622.USD","LU0058720904.USD","GLAM","LU0234572021.USD","LU1236620834.HKD","LU2023251221.USD","LU2125909593.SGD","IXJ","AGNG","LU0965508806.USD","LU0128525929.USD","LU0472753341.HKD","TRUH","XLV","ABBV","IPOS","BK4559","IE00BLSP4239.USD","LU2125909247.SGD","PJP","MEDX","LU1732799900.SGD","LU0417517546.SGD","LU2087621335.USD","LU0985320562.USD","LU0882574055.USD","LU1839511570.USD","LU1989771016.USD","IE0004445239.USD","VHT","LU1236620750.USD","PPH","EMA","LU0198837287.USD","LU2089283258.USD","FTXH","JDOC","IE000F7OJYX1.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662200130","title":"中化国际EMA项目投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2662200130","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662200130?lang=zh_cn&edition=full","pubTime":"2026-08-25 10:09","pubTimestamp":1787623784,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657648031","title":"Emera（EMA）上半年调整后净利润增至6.27亿加元、净收入降至6.67亿加元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657648031","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657648031?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:34","pubTimestamp":1786102483,"startTime":"0","endTime":"0","summary":"金吾财讯 | 北美能源巨头Emera 公布2026年第二季度及上半年财务业绩。2026年二季度，Emera实现调整后净利润2.12亿加元，较上年同期的2.36亿加元有所放缓；净利润为1.05亿加元。2026年上半年，公司调整后净利润达到6.27亿加元，高于2025年上半年的6.15亿加元。期内净收入为6.67亿加元，低于去年同期的7.18亿加元。展望未来，公司预计，2026年调整后每股收益增长将超越其5%-7%的年度目标区间高位，公司重申截至2030年维持5%-7%的复合年均增长承诺。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNGMxNzgxNjk0YjcxNTczNmY1MTEwODUxNDQzMTc3Ng==.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303564","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148281703","title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1148281703","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148281703?lang=zh_cn&edition=full","pubTime":"2026-07-31 08:42","pubTimestamp":1785458557,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年08月07日盘前发布第二季度财报，市场预期营收增长而利润承压，投资者关注盈利质量与现金流稳定性。一致预期显示，本季度Emera Inc.营收为20.29亿加元，同比增长15.89%；调整后每股收益为0.49加元，同比下降24.17%；EBIT为4.73亿加元，同比增长1.23%，上一季度未披露针对本季度的明确量化指引。上季度公司实现营收28.13亿加元，同比增长5.12%；毛利率50.20%；归属于母公司股东的净利润5.82亿加元，净利率20.69%；调整后每股收益同比增长7.00%，净利润环比增长568.97%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增15.89%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654001188","title":"瑞博生物-B：核心产品VORTOSIRAN针对SPAF的2B期临床试验获EMA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2654001188","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654001188?lang=zh_cn&edition=full","pubTime":"2026-07-28 19:59","pubTimestamp":1785239982,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","PSYK","BK4081","MDTX","BMED","IBBJ","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647037238","title":"Rocket Lab股价站稳200日EMA上方：获NASA合同后是否值得买入？","url":"https://stock-news.laohu8.com/highlight/detail?id=2647037238","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647037238?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:09","pubTimestamp":1782738540,"startTime":"0","endTime":"0","summary":"Rocket Lab股价周一盘前交易时段上涨，此前该公司宣布将收购卫星通信运营商Iridium，交易价值约80亿美元。这一消息叠加近期获得的NASA发射合同，为股价提供了技术面支撑。　　从技术走势来看，Rocket Lab股价在6月25日跌至80.69美元的低点后获得支撑，目前盘前交易于90美元附近，成功站稳200日指数移动平均线上方。　　上周，NASA宣布选择Rocket Lab执行三项Electron火箭发射任务，用于PolSIR和TSIS-2科学任务，预计于2027年初启动。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-29/doc-inifauhn5315358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4081","300785","BK0217","EMA","NASA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645409710","title":"恒瑞医药(600276.SH)：瑞维鲁胺片上市许可申请获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645409710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645409710?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:38","pubTimestamp":1782117505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到了欧洲药品管理局(European Medicines Agency，简称“EMA”)的通知,EMA正式确认并受理公司递交的瑞维鲁胺片的上市许可申请，这是公司首个自主研发的创新药向欧盟递交上市申请。该药品适用于联合雄激素剥夺治疗(ADT)，治疗高瘤负荷的转移性激素敏感性前列腺癌(mHSPC)成年男性患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456886.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","LU1997245094.SGD","LU2488822045.USD","LU1255011170.USD","LU2495084118.USD","BK1191","BK0188","LU1328615791.USD","LU0359202008.SGD","LU1146622755.USD","LU1064131003.USD","BK0196","EMA","LU1781817850.SGD","LU0405327494.USD","BK0012","LU1064130708.USD","BK0060","LU0359201885.HKD","IPOS","LU1997245177.USD","LU1655091616.SGD","BK0028","LU1580142542.USD","LU2097828714.EUR","LU2097828631.EUR","BK0183","LU0359201612.USD","LU0405327148.USD","LU2097828557.USD","LU2580892789.USD","600276","LU2289578879.USD","LU2543165471.USD","LU2580892862.HKD","LU1023057109.AUD","BK4081","LU1969619763.USD","LU2097828805.USD","LU2148510915.USD","LU2328871848.SGD","LU1997244956.HKD","01276","LU1820825898.SGD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185761853","title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","url":"https://stock-news.laohu8.com/highlight/detail?id=1185761853","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185761853?lang=zh_cn&edition=full","pubTime":"2026-05-01 08:17","pubTimestamp":1777594630,"startTime":"0","endTime":"0","summary":"Emera Inc.将于2026年05月08日公布最新季度业绩，市场关注营收增速与成本控制的落地情况。根据一致预期，本季度Emera Inc.营收预计为30.09亿加元，同比增长35.49%；调整后每股收益预计为1.15加元，同比增长15.55%；息税前利润预计为7.02亿加元，同比增长7.05%；当前一致预期未提供本季度毛利率及净利润或净利率的具体预测。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Emera Inc.本季度营收预计增35.49%，盈利质量成看点","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627213629","title":"罗氏获欧洲监管机构反馈后，启动Elevidys基因疗法新研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2627213629","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2627213629?lang=zh_cn&edition=full","pubTime":"2026-04-16 20:44","pubTimestamp":1776343440,"startTime":"0","endTime":"0","summary":"罗氏公司周四宣布，在收到欧洲药品监管机构的反馈后，将针对其基因疗法 Elevidys 启动一项晚期临床试验。该疗法用于治疗杜氏肌营养不良症，由罗氏与美国 Sarepta Therapeutics 公司合作研发。此前，因两例患者死亡事件与该疗法相关而引发审查，这款药物去年未能获得欧洲药品管理局的批准。Elevidys 目前已在 9 个国家获批用于可自主行走、确诊携带 DMD 基因突变的男孩，其中包括美国。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-16/doc-inhuszrw2800982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EMA","BK4081"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624593383","title":"港股异动 | 和誉-B(02256)盘中涨近10% FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2624593383","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2624593383?lang=zh_cn&edition=full","pubTime":"2026-04-01 15:57","pubTimestamp":1775030256,"startTime":"0","endTime":"0","summary":"消息面上，和誉宣布，其自主研发的高选择性小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。除本次获得EMA孤儿药资格外，依帕戈替尼此前还分别获得了美国食品药品监督管理局授予的ODD和快速通道资格认定，以及中国国家药品监督管理局授予的突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","LU2488822045.USD","LU2778985437.USD","VXUS","IE00BPRC5H50.USD","BK4588","LU2476274308.USD","BK1161","LU2476274720.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK4585","EMA","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623581546","title":"和誉-B(02256)：FGFR4抑制剂依帕戈替尼获EMA授予孤儿药资格，用于治疗肝细胞癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2623581546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2623581546?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:32","pubTimestamp":1774960347,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B 发布公告，公司附属公司上海和誉生物医药科技有限公司宣布，其自主研发的高选择性口服小分子FGFR4抑制剂依帕戈替尼已获得欧洲药品管理局授予的孤儿药资格，用于治疗肝细胞癌。目前，依帕戈替尼正在全球多地开展临床研究，此次获EMA授予ODD，将为该产品在欧洲的临床开发、注册申报与商业化进程提供有力支持。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4081","IE00B543WZ88.USD","LU2476274308.USD","02256","BK1161","IE00B5MMRT66.SGD","LU2488822045.USD","IE00BPRC5H50.USD","EMA","LU2476274720.SGD","LU2778985437.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.emera.com","stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.0444},{"period":"3month","weight":-0.056},{"period":"6month","weight":-0.0464},{"period":"1year","weight":0.0569},{"period":"ytd","weight":-0.0071}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0241},{"period":"3month","weight":0.0098},{"period":"6month","weight":0.1626},{"period":"1year","weight":0.1425},{"period":"ytd","weight":0.1058}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Emera Inc.于1998年7月23日在加拿大注册成立，是一家北美能源服务提供商，拥有并经营服务成本、费率管制的电力和天然气公用事业组合。该公司最大的业务在佛罗里达州，并在加拿大大西洋省、新墨西哥州和加勒比地区增加了业务。Emera总部位于新斯科舍省哈利法克斯，其业务战略侧重于对其受监管的公用事业、卓越运营和效率进行持续投资，以便为其270万客户可靠地提供能源。公司在受监管公用事业的盈利机会取决于净投资规模、资本结构权益和目标回报，这些都是通过监管建立起来的。","exchange":"NYSE","name":"Emera Inc.","nameEN":"Emera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Emera Inc.,EMA,Emera Inc.股票,Emera Inc.股票老虎,Emera Inc.股票老虎国际,Emera Inc.行情,Emera Inc.股票行情,Emera Inc.股价,Emera Inc.股市,Emera Inc.股票价格,Emera Inc.股票交易,Emera Inc.股票购买,Emera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Emera Inc.(EMA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Emera Inc.(EMA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}